File photo/NBD

On the evening of April 25th, BGI Genomics released its Q1 2023 report.

The top three shareholders of BGI Genomics saw changes in their holdings in the first quarter, with two fund companies increasing their holdings.

According to data, the third largest shareholder, Bank of Communications Co., Ltd. - E Fund Industry Selection Hybrid Securities Investment Fund (LOF), increased its holdings by 2.333 million shares, increasing its shareholding ratio to 2.98%.

The fourth largest shareholder, Hong Kong Securities Clearing Company Limited (Stock Connect), reduced its holdings by 537,000 shares, decreasing its shareholding ratio to 1.84%.

And the fifth largest shareholder, Bank of China Limited - Huabao CSI Medical Trading Open-End Index Securities Investment Fund, increased its holdings by 217,000 shares, increasing its shareholding ratio to 1.05%.

In addition, there are two new shareholders among the top ten shareholders of BGI Genomics.

Over the past three years, BGI Genomics' monetary funds have grown significantly. As of the end of 2019, BGI Genomics' had money of RMB 735 million. By the end of 2022, the amount increased to RMB 5.158 billion, and in Q1 2023, they reached RMB 5.333 billion.

Looking to the future, where will the company's profit growth come from?

BGI Genomics stated that it will increase investment, particularly in the core business areas of reproductive health, tumor prevention and control, and the prevention and control of existing infectious diseases, as well as in the field of chronic diseases. In terms of business models, it will explore new business models.